Repair and recovery
KPV, thymosin beta-4, TB-500 and BPC-157: a real preclinical literature and a missing clinical one.
Covered here: BPC-157 · TB-500
The repair peptides are a loose group named for what researchers hoped they would do rather than for anything they share structurally. KPV is a three-amino-acid fragment, lysine-proline-valine, taken from the tail end of alpha-melanocyte-stimulating hormone, and most of its published work is anti-inflammatory research in cell and animal models of intestinal inflammation. Thymosin beta-4 is a different kind of thing: a 43-amino-acid protein that occurs naturally in nearly every human cell, where it regulates actin, and which is concentrated in wound fluid.
TB-500 and thymosin beta-4 are not synonyms, which is the single most useful fact about this group. Thymosin beta-4 is the full protein and it carries the published biology. TB-500, the research-market name, usually refers to a synthetic fragment of that protein, commonly the actin-binding region, and a fragment does not inherit its parent protein’s literature. BPC-157 sits in the same bracket from a different direction: a large, genuine, two-decade rodent literature, and no completed randomised human trial for any indication.
That shape, real preclinical science alongside a missing clinical record, is why this group attracts the most confident claims online and supports the fewest. Asking whether any of it is safe has one honest answer: safety in humans is a finding, not a default, and for most of these compounds the finding has not been published. Our repair review names what each investigator reported and the model it was reported in.
Common questions
What is KPV?
KPV is a tripeptide, lysine-proline-valine, corresponding to the C-terminal three residues of alpha-melanocyte-stimulating hormone. Research interest in it is anti-inflammatory, and the published work sits in cell culture and animal models, much of it in models of intestinal inflammation. There is no completed randomised human trial of KPV for any indication.
What is thymosin beta-4, and how does it work?
Thymosin beta-4 is a naturally occurring 43-amino-acid protein present in nearly all human cells and concentrated in wound fluid. Its established biological role is in actin regulation, which is why it is studied in wound healing and tissue repair. Mechanism and clinical effect are separate claims: early-phase human trials of the full protein in dermal and corneal wound healing reported safety and mixed efficacy signals, and the programme did not reach approval.
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is the complete 43-amino-acid protein and the subject of the published literature. TB-500 is a research-market name that usually refers to a synthetic fragment of it, commonly the actin-binding region around residues 17 to 23. A certificate can show that a vial contains a peptide of the expected mass. It cannot transfer the parent protein’s research record to a fragment of it.
What does the published work on TB-500 and BPC-157 report?
For BPC-157, dozens of peer-reviewed animal studies, largely from one research group, report accelerated healing across injury models in rats at researcher-controlled doses. For thymosin beta-4, there is a real endogenous biological role plus early-phase human safety data for the full protein. What has not been published for either is a completed randomised human efficacy trial, and for most of the fragments sold under research names there is no published human data at all.
Are BPC-157 and TB-500 safe?
Neither is FDA-approved for any indication, and neither has a published human safety dataset of the kind an approval requires. Absence of reported harm in a market with no reporting system is not a safety finding. The compounds in this field with human safety data are the ones that went through trials, and these did not.
What are gut peptides?
Gut peptides is an informal label covering two unrelated things: hormones genuinely produced in the gastrointestinal tract, such as GLP-1 and GIP, and compounds studied in models of intestinal inflammation or barrier function, such as KPV and BPC-157. The first group includes the most heavily trialled peptides in modern medicine. The second is almost entirely preclinical. Grouping them under one phrase makes the evidence look more uniform than it is.
Read the evidence
3 pieces on this subject, every finding attributed and every gap stated.
Related topics
For research use only · Not for human or veterinary use · No compound discussed here is FDA-approved for any indication